Table 7. The distribution of CD166 staining and CD166 KRAS exon 2 mutation status with the post-treatment outcome of CRC patients.

	Poor-treatment outcome (25)	Good-treatment outcome (45)
CD166-positive staining	22/25 (88%)	27/45 (60%)
CD166-negative staining	3/25 (12%)	18/45 (40%)
Positive KRAS exon 2 mutations without macrodissection	9/25 (36%)	16/45 (36%)
Negative KRAS exon 2 mutations without macrodissection	16/25 (64%)	29/45 (64%)
Positive KRAS exon 2 mutations in CD166-positive cells	19/25 (76%)	10/45 (22%)
Negative KRAS exon 2 mutations in CD166-positive cells	4/25 (16%)	16/45 (36%)